Senate Expected To Vote On US FDA User-Fee Bill August 3
Executive Summary
Senate Majority Leader Mitch McConnell, R-Kent., filed cloture on H.R. 2430, the FDA Reauthorization Act on device and drug user fees this week, and indicated debate and a vote on the bill will likely take place on Aug. 3.
You may also be interested in...
Senate Approves FDA User Fee Reauthorization Bill On 94-1 Vote
The Senate Aug. 3 swiftly approved the FDA Reauthorization Act (FDARA) on a 94-1 vote. The president is expected to sign the bill, which previously passed the House and will enact the MDUFA IV user-fee agreement and make reforms tied to device accessory review, device facility inspections, and medical imaging FDA reviews.
US FDA User-Fee Bill Swiftly Passes US House, Now Moves To Senate
The FDA Reauthorization Act, which would reauthorize the MDUFA IV user-fee agreement and enact additional device regulatory reforms, passed the US House July 12 on a unanimous vote. Lawmakers applauded the bill's inclusion of device facility inspection reforms and an over-the-counter hearing aid provisions. The legislation now moves to the Senate, where a crowded legislative schedule could mean delayed consideration.
Outlook 2023: Market Experts On Importance Of Value, Mental Health In A ‘World On Fire’
Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.